Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IART 
Integra LifeSciences Holdings (IART)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: IART (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $15.88
1 Year Target Price $15.88
| 2 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 2 | Sell |
| 2 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -57.98% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.17B USD | Price to earnings Ratio - | 1Y Target Price 15.88 |
Price to earnings Ratio - | 1Y Target Price 15.88 | ||
Volume (30-day avg) 12 | Beta 1.2 | 52 Weeks Range 11.06 - 27.13 | Updated Date 09/14/2025 |
52 Weeks Range 11.06 - 27.13 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.54 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -30.87% | Operating Margin (TTM) 7.86% |
Management Effectiveness
Return on Assets (TTM) 2.43% | Return on Equity (TTM) -38.92% |
Valuation
Trailing PE - | Forward PE 6.15 | Enterprise Value 2933497497 | Price to Sales(TTM) 0.72 |
Enterprise Value 2933497497 | Price to Sales(TTM) 0.72 | ||
Enterprise Value to Revenue 1.81 | Enterprise Value to EBITDA 14.27 | Shares Outstanding 77910800 | Shares Floating 59271413 |
Shares Outstanding 77910800 | Shares Floating 59271413 | ||
Percent Insiders 13.97 | Percent Institutions 95.31 |
Upturn AI SWOT
Integra LifeSciences Holdings
Company Overview
History and Background
Integra LifeSciences was founded in 1989. It focuses on regenerative medicine and neurosurgery. Over time, Integra has grown through product development and strategic acquisitions, expanding its portfolio to address unmet needs in surgical procedures and tissue regeneration.
Core Business Areas
- Codman Specialty Surgical (CSS): CSS focuses on neurosurgery products, including devices for hydrocephalus management, intracranial pressure monitoring, and neurosurgical tools. They also offer a range of surgical instruments and accessories.
- Tissue Technologies: This segment includes products for advanced wound care, burns, and reconstructive and general surgery. Products include skin grafts, wound dressings, and tissue repair matrices.
Leadership and Structure
Integra LifeSciences is led by a CEO and a senior management team overseeing different business functions. The organizational structure is divided into business units and supporting departments like finance, R&D, and marketing.
Top Products and Market Share
Key Offerings
- DuraGen: A dural regeneration matrix used in neurosurgery to repair dura mater defects. Competitors include Medtronic (MDT), Johnson & Johnson (JNJ), and Baxter (BAX). Market share data is unavailable publicly for this specific product but DuraGen is a key revenue generator for Integra in neurosurgery.
- CereLink ICP Monitor: An intracranial pressure monitoring system. Competitors include Medtronic (MDT) and Raumedic. Market share data is unavailable publicly for this specific product.
- PriMatrix: A dermal repair scaffold used for wound healing and reconstructive surgery. Competitors include Acelity (now 3M) and Smith & Nephew (SNN). Revenue from this product is unavailable publicly.
Market Dynamics
Industry Overview
The medical technology industry is characterized by innovation, regulatory scrutiny, and competitive pressures. Demand is driven by an aging population, increasing prevalence of chronic diseases, and advancements in surgical techniques.
Positioning
Integra LifeSciences holds a position in the regenerative medicine and neurosurgery markets, with a focus on specialized surgical solutions and advanced wound care. Its competitive advantages lie in its proprietary technologies and established relationships with surgeons and hospitals.
Total Addressable Market (TAM)
The TAM for Integra's key market segments (neurosurgery and advanced wound care) is estimated to be in the billions of dollars. Integra is well-positioned to capture a portion of this TAM through product innovation and market expansion.
Upturn SWOT Analysis
Strengths
- Specialized Product Portfolio
- Strong Brand Reputation in Neurosurgery
- Established Distribution Network
- Focus on Innovation
Weaknesses
- Reliance on Acquisitions for Growth
- Limited Market Share in Certain Segments
- Exposure to Product Liability Risks
- High debt level
Opportunities
- Expansion into Emerging Markets
- Development of New Regenerative Medicine Therapies
- Strategic Partnerships and Collaborations
- Increasing demand for minimally invasive surgical procedures
Threats
- Intense Competition
- Pricing Pressures
- Regulatory Changes
- Economic Downturn
Competitors and Market Share
Key Competitors
- MDT
- JNJ
- BAX
- SNY
Competitive Landscape
Integra competes with larger, more diversified medical device companies. Its competitive advantages lie in its specialized product portfolio and focus on niche markets. However, it faces challenges from competitors with greater resources and broader market reach.
Major Acquisitions
Acclarent
- Year: 2023
- Acquisition Price (USD millions): 263500000
- Strategic Rationale: Acquired Acclarent from Johnson & Johnson. Expansion of its ENT portfolio, new technology, and broader market reach.
Growth Trajectory and Initiatives
Historical Growth: Integra LifeSciences has grown both organically and through acquisitions, expanding its product portfolio and market reach.
Future Projections: Analysts project continued revenue growth driven by new product launches and market expansion.
Recent Initiatives: Recent initiatives include strategic acquisitions, product development, and restructuring efforts to improve efficiency.
Summary
Integra LifeSciences is a player in regenerative medicine and neurosurgery. It has a specialized product portfolio and a strong brand reputation in neurosurgery. High debt and reliance on acquisitions are areas that needs attention. Overall, Integra appears to be on solid ground within their markets, yet external threats will likely have an impact.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Analyst Reports
- Industry News and Publications
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Integra LifeSciences Holdings
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 1995-08-16 | President, CEO & Director Ms. Mojdeh Poul | ||
Sector Healthcare | Industry Medical Devices | Full time employees 4396 | Website https://www.integralife.com |
Full time employees 4396 | Website https://www.integralife.com | ||
Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company addresses the needs of plastic, and reconstructive and general surgeons focused on the treatment of acute wounds, such as burns and chronic wounds, including diabetic foot ulcers; and provides surgical tissue repair products for hernia, tendon, peripheral nerve repair, and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. Further, it is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.